technology pic
HomeSite MapContact Us
technology
Results are sorted by title (sort by update date)
13 technologies found
page 1 of 1
Prostate cancer (CaP), an adenocarcinoma of the prostate, is the most common cancer in American males over the age of 55 and the second cause of cancer-related mortality. The current diagnosis of prostate cancer is based on the measurements of serum prostate-specific antigen (PSA) levels. ...
A test method based on a genetic polymorphism in the Haptoglobin gene identifies those individuals with Diabetes who are at high risk for developing heart, eye and kidney disease and who benefit from specific drug treatments, has been validated in multiple clinical trials worldwide. Diabetes is ...
A kit which greatly shortens time and improves accuracy required to diagnose blood coagulation problems, and improves the design of personalized treatment regimen, is being developed by Prof. Brenner and Dr. Aharon and clinically tested and the Rambam Medical center Hypercoagulation is a term ...
BioRap Technologies and the Lipid Research Laboratory of the Rappaport Family Institute are offering collaboration for the identification of antioxidant and anti - atherogenic properties of nutritional antioxidants The lipid research laboratory, headed by Professor Michael Aviram, focuses its ...
Prof. Lior Gepstein's hiPSCs (human induced pluripotent stem cells) approach for modeling inherited cardiac disorders, such as Pompe glycogen storage disease, congenital long QT syndrome type II, CPVT and ARVC, has many implications in cardiovascular regenerative medicine, drug discovery, disease ...
An innovative platform for drug screening, toxicology testing and exploration of nevel means for treating severe cardiac pathologies, has been generated by Prof. Binah, focusing on inherited cardiac diseases such as Long Q-T Syndrome (LQTS), Catecholaminergic Polymorphic Ventricular Tachycardia ...
Professor Gera Neufeld, a member of the Rappaport Family Institute for Research in the Medical Sciences, Haifa, Israel, studies tumor angiogenesis and investigates the molecular mechanisms that contribute to the development and progression of cancer. Vascular endothelial growth factor (VEGF) ...
A new paradigm: identifying host targets rather than tumor targets as cancer drugs, specifically in situations of tumor relapse, is shown to significantly improve clinical outcome of conventional cancer therapies. This platform strategy is also investigated for predictive and prognostic biomarkers ...
One of the obstacles in clinical oncology is that tumors sometimes acquire resistance to therapy and spread. Throughout the years, various therapeutic agents have been developed aiming to directly target tumor cells or inhibit tumor-supporting cells in its microenvironment. The development of ...
Optogenetics approaches, utilizing light-sensitive proteins, have emerged as unique experimental paradigms to modulate neuronal excitability and have consequentially revolutionized neuroscience. The group of Dr. Lior Gepstein is developing similar strategies to also control cardiac-tissue ...
The identification of a specific epitope in EMMPRIN that has a role in the induction of both MMP-9 and VEGF, has brought about the development of two novel immunotherapy approached targeting EMMPRIN - A multiple antigenic peptide and a binding antibody. Macrophages heavily infiltrate solid ...
BeautyGene provides personalized cosmetics matching service based on one’s genetic code. Initial proof of concept had shown the ability to define person's skin shade by his/her DNA signature. BeautyGene uses DNA markers together with proprietary DNA Database and algorithm for personalized ...
Prof. Youdim, a ground breaking researcher, is listed as an inventor in over 90 patents dealing with neurodegenerative diseases. His research has greatly increased the scientific community's understanding of the processes involved in the development of these diseases and has led to the ...
1

*TTO - Technology Transfer Organization
ITTN - Israel Tech Transfer Organization